Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology

Autor: Francisca Martínez, Johan Smitz, Arne van der Vijver, Evangelos Evangelou, Christian De Geyter, Panagiotis Drakopoulos, Nikolaos P. Polyzos, Antonio Gosalvez Vega, Herman Tournaye, Susan R. Davis, Peter Humaidan, Pedro N. Barri
Přispěvatelé: Surgical clinical sciences, Faculty of Medicine and Pharmacy, Follicle Biology, Pathology/molecular and cellular medicine, Biology of the Testis, Centre for Reproductive Medicine - Gynaecology, Clinical Biology
Rok vydání: 2018
Předmět:
0301 basic medicine
Infertility
Testosterone Excess
medicine.medical_specialty
medicine.drug_class
Androgens/pharmacokinetics
Fertilization in Vitro
Fertilization in Vitro/methods
Ovary/drug effects
Poor responders
CLINICAL-TRIAL
poor responders
03 medical and health sciences
0302 clinical medicine
Ovulation Induction
poor ovarian response
TESTOSTERONE
Internal medicine
Obstetrics and Gynaecology
Follicular phase
medicine
Humans
Sperm Injections
Intracytoplasmic
Testosterone/pharmacokinetics
Randomized Controlled Trials as Topic
030219 obstetrics & reproductive medicine
business.industry
Ovary
Obstetrics and Gynecology
Testosterone (patch)
Androgen
medicine.disease
TRANSDERMAL TESTOSTERONE
Androgen receptor
Treatment Outcome
030104 developmental biology
Endocrinology
testosterone
Androgens
Female
Folliculogenesis
Animal studies
infertility
business
Zdroj: Polyzos, N P, Davis, S R, Drakopoulos, P, Humaidan, P, De Geyter, C, Vega, A G, Martinez, F, Evangelou, E, van de Vijver, A, Smitz, J, Tournaye, H, Barri, P & T-TRANSPORT Investigators Group 2018, ' Testosterone for Poor Ovarian Responders : Lessons From Ovarian Physiology ', Reproductive Sciences, vol. 25, no. 7, pp. 980-982 . https://doi.org/10.1177/1933719116660849
ISSN: 1933-7205
1933-7191
DOI: 10.1177/1933719116660849
Popis: Testosterone, an androgen that directly binds to the androgen receptor, has been shown in previous small randomized controlled trials to increase the reproductive outcomes of poor ovarian responders. In most of these studies, transdermal testosterone in relatively high doses was administered before ovarian stimulation with a duration varying from 5 to 21 days. Nevertheless, the key question to be asked is whether, based on ovarian physiology and testosterone pharmacokinetics, a short course of testosterone administration of more than 10 mg could be expected to have any beneficial effect on reproductive outcome. The rationale for asking this question lies in the existing scientific evidence derived from basic research and animal studies regarding the action of androgens during folliculogenesis, showing that their main effect in follicular development is defined during the earlier developmental stages. In addition, extreme testosterone excess is not only likely to induce adverse events but has also the potential to be ineffective and even detrimental. Thus, evidence from clinical studies is not enough to either "reopen" or "close" the "androgen chapter" in poor responders, mainly because the short administration and the high dose of testosterone is not in line with the ovarian actions of androgens and the presence of androgen receptors during follicular development.
Databáze: OpenAIRE
Externí odkaz: